Replies to post #106344 on Biotech Values

[jq1234]

I don't think it has that much to do with key people left. They overpaid for DNA. For acquisition of that size, they should have waited for Avastin in earlier colon cancer trial result to evaluate Avastin overall potential in earlier stage cancer. Sure, they would have to pay more if Avastin succeeded, but it would be worth it. You don't take chance in acquisition of that size. Now, it is pretty much confirmed from several other failed trials that Avastin doesn't improve survival in earlier stage of cancer. I don't think Roche can recover for awhile until new drugs come to fruition to replace lost projected revenue from Avastin.

[DewDiligence]

I think Roche’s leveraging the balance sheet to own 100% of Genentech instead of 56% was the right thing to do despite the recent defections and clinical setbacks.